BioCryst Pharmaceuticals (BCRX) analyst forecast and price target
Analyst forecast
Consensus of 11 analyst ratings
Based on 5 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wedbush | Maintained | Outperform | $20.00 from $21.00 | Aug 6, 2026 |
| RBC Capital | Maintained | Outperform | $13.00 from $14.00 | Aug 6, 2026 |
| JP Morgan | Maintained | Neutral | $12.00 | Jul 13, 2026 |
| RBC Capital | Maintained | Outperform | $14.00 from $13.00 | Jul 7, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $29.00 from $27.00 | Jun 30, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $32.00 | Jun 30, 2026 |
| Wedbush | Maintained | Outperform | $21.00 from $22.00 | May 7, 2026 |
| Citizens | Maintained | Market Outperform | $28.00 from $25.00 | May 7, 2026 |
| Needham | Maintained | Buy | $16.00 from $18.00 | May 6, 2026 |
| RBC Capital | Maintained | Outperform | $13.00 from $14.00 | Jan 30, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $32.00 from $30.00 | Dec 15, 2025 |
| Citizens | Maintained | Market Outperform | $25.00 from $27.00 | Nov 5, 2025 |
| Needham | Maintained | Buy | $18.00 from $20.00 | Nov 4, 2025 |
| Barclays | Maintained | Equal-Weight | $9.00 from $11.00 | Nov 4, 2025 |
| Needham | Maintained | Buy | $20.00 from $17.00 | Oct 15, 2025 |
| Cantor Fitzgerald | Maintained | Overweight | $26.00 from $24.00 | Oct 15, 2025 |
| TD Cowen | Maintained | Buy | $30.00 | Oct 15, 2025 |
| JMP Securities | Maintained | Market Outperform | $27.00 from $17.00 | Oct 15, 2025 |
| Needham | Maintained | Buy | $17.00 | Aug 4, 2025 |
| B of A Securities | Maintained | Buy | $15.00 from $13.00 | Jul 1, 2025 |
Frequently asked questions
What is the price target for BCRX stock?
The average 12-month analyst price target for BioCryst Pharmaceuticals (BCRX) is $21.20, with a high estimate of $32.00 and a low of $12.00, across 5 analysts.
Is BCRX a buy, sell, or hold?
Analysts covering BioCryst Pharmaceuticals currently average a Buy rating: 10 buy, 1 hold and 0 sell, from 11 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for BCRX?
The average price target of $21.20 implies 118.56% upside from the last price of $9.70.
What is the latest analyst rating on BCRX?
On Aug 6, 2026, Wedbush maintained BioCryst Pharmaceuticals at Outperform with a price target of $20.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.